EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

DPYD Genotyping of Patients with Fluoropyrimidine Treatment: Results of Protocol Implementation and Outcomes of Patients Carrying Unusual DPYD Variants

Josefa Salgado Garrido iD, Alba Alonso Llorente, Oscar Teijido Hermida iD, Juan José Beloqui Lizaso iD, Rosana Grández Ladrón de Guevara, Elena Mata Velasco, Ruth Vera García, Alberto Valiente Martín

Genes · 26.06.2026 · 17 (7) · 741

DOI: 10.3390/genes17070741 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Genes, online erschienen am 26.06.2026. Verfasst von Josefa Salgado Garrido und 7 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Genética Médica del Hospital Universitario de Navarra (HUN), 31008 Pamplona, Navarra, Spain. Hauptthemen laut MEDLINE: Dihydrouracil Dehydrogenase (NADP), Fluorouracil. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: The DPYD gene encodes the enzyme dihydropyrimidine dehydrogenase that metabolizes fluoropyrimidines. Genetic variants in DPYD have been associated with altered enzyme activity; therefore, accurate detection and interpretation is critical for individualized fluoropyrimidine therapy. The most common causal variant is c.1129-5923C>G (rs75017182) located in intron 10, which introduces a cryptic splice site. This variant is in high linkage disequilibrium (LD) in the HapB3 haplotype with a benign synonymous variant in exon 11, c.1236G>A (rs56038477). Since c.1129-5923C>G and c.1236G>A have been reported in LD, many commercial kits use c.1236G>A as a proxy for the function-altering intronic variant.

Methods

A DPYD genotyping protocol was implemented following the quality regulations that apply to clinical laboratories (EN-ISO9001:2015 and EN-ISO15189:2022). NGS, MLPA and Sanger sequencing were used for validation purposes.

Results

Over the last 5 years a total of 2007 patients have been analyzed at our department. The observed DPYD genotype frequencies aligned with those observed in European populations. Importantly, we have identified a patient harboring the c.1236G>A variant, but in the absence of the c.1129-5923C>G variant. This last result supports recently published findings suggesting that these two variants may not be in perfect LD, as previously assumed, and lead to suboptimal dosing for those patients carrying this allele. Finally, low frequency variants (c.496A>G, c.2194G>A, and c.1601G>A), not described in DPYD analysis guidelines recommendations, were found in two patients who required fluoropyrimidines dose adjustment.

Conclusions

These findings highlight the limitations of relying on proxy variants for clinical decision-making, as incomplete linkage disequilibrium may lead to misclassification of patients’ metabolic capacity. Furthermore, in order to provide safer protocols for DPYD-based personalized treatment genetic panels should expand to include additional rare DPYD variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dihydrouracil Dehydrogenase (NADP)FluorouracilHumansGenotypePolymorphism, Single NucleotideGenotyping TechniquesLinkage DisequilibriumFemale

Stichwörter der Autor:innen

DPYDHapB3genotypingrare variants

Substanzen

Dihydrouracil Dehydrogenase (NADP)Fluorouracil

Autor:innen und Institutionen

  • Servicio de Genética Médica del Hospital Universitario de Navarra (HUN), 31008 Pamplona, Navarra, Spain.
  • Departamento de Bioquímica y Biología Molecular, Universidad Pública de Navarra (UPNA), 31006 Pamplona, Navarra, Spain.
  • Servicio de Análisis Clínicos del Hospital Universitari Arnau de Vilanova de Lleida, 25198 Lleida, Catalunya, Spain.
  • IRBLleida, Institut de Recerca Biomèdica de Lleida Fundació Dr. Pifarre, 25198 Lleida, Catalunya, Spain.
  • Departamento de Ciencias de la Salud, Universidad Pública de Navarra (UPNA), 31006 Pamplona, Navarra, Spain.
  • Servicio de Farmacia del Hospital Universitario de Navarra (HUN), 31008 Pamplona, Navarra, Spain.

ORCID-Profile: Josefa Salgado Garrido, Oscar Teijido Hermida, Juan José Beloqui Lizaso

Zitieren

APA

Salgado Garrido, J., Alonso Llorente, A., Teijido Hermida, O., Beloqui Lizaso, J. J., Grández Ladrón de Guevara, R., Velasco, E. M., Vera García, R., & Valiente Martín, A. (2026). DPYD Genotyping of Patients with Fluoropyrimidine Treatment: Results of Protocol Implementation and Outcomes of Patients Carrying Unusual DPYD Variants. Genes, 17(7), 741. https://doi.org/10.3390/genes17070741

Vancouver

Salgado Garrido J, Alonso Llorente A, Teijido Hermida O, Beloqui Lizaso JJ, Grández Ladrón de Guevara R, Velasco EM, et al. DPYD Genotyping of Patients with Fluoropyrimidine Treatment: Results of Protocol Implementation and Outcomes of Patients Carrying Unusual DPYD Variants. Genes. 2026;17(7):741. doi:10.3390/genes17070741

BibTeX
@article{SalgadoGarrido2026,
  author = {Salgado Garrido, Josefa and Alonso Llorente, Alba and Teijido Hermida, Oscar and Beloqui Lizaso, Juan José and Grández Ladrón de Guevara, Rosana and Velasco, Elena Mata and Vera García, Ruth and Valiente Martín, Alberto},
  title = {DPYD Genotyping of Patients with Fluoropyrimidine Treatment: Results of Protocol Implementation and Outcomes of Patients Carrying Unusual DPYD Variants},
  journal = {Genes},
  year = {2026},
  volume = {17},
  number = {7},
  pages = {741},
  doi = {10.3390/genes17070741}
}
Kostenlos starten →